We have found that patients with high expression levels of IGF2BP1 and IGF2BP3 have statistically significant poorer survival rates compared to those whose melanoma cells had low IGF2BP1 and IGF2BP3 levels (Figure 5B). This evidence concerns the gene IGF2BP1 and melanoma.